Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab ± IBI305 + Chemo in EGFR-mutant NSCLC (ORIENT-31)
NCT03802240Phase 3Completed
- Sponsor
- Innovent Biologics
- Start
- Jul 2019
- Primary completion
- Jul 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of sintilimab, bevacizumab in non-small cell lung cancer (NSCLC), sponsored by Innovent Biologics. Started Jul 2019; status: completed.
02
Drugs
sintilimabbevacizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03802240.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03802240.